Optimi Health Discloses Terms of US$100M Equity Line with Seven Knots
OPTH sits 57% above its 52-week low of $3.12 on light trading volume (0.1× avg).
Summary
Optimi Health disclosed the detailed terms of its US$100 million equity line of credit with Seven Knots, including a US$1.5 million convertible commitment note, discount draw pricing, and a pending Form F-1 registration.
Key Events · Financing and Capital Events · OPTH
-
US$100M Equity Line Terms Disclosed
Optimi Health entered a common shares purchase agreement with Seven Knots, LLC on August 13, 2026, establishing a US$100 million equity line of credit with draws at the company's discretion.
-
Commitment Notes Issued
The company issued a US$1.5 million unsecured, non-interest-bearing convertible note to Seven Knots, with a second US$500,000 note due if ELOC gross proceeds reach US$7 million. Notes mature in 24 months and convert at 95% of the 20-day VWAP with a US$3.00 floor.
-
Draw Pricing Mechanics
Each draw is priced at 97% of the lower of the lowest sale price on the purchase date or the VWAP during the purchase period, capped at US$2 million per draw, with a floor at 85% of the prior-day closing price.
-
Ownership Blocker
Seven Knots and its affiliates cannot beneficially own more than 2.99% of Optimi's outstanding common shares upon conversion of the Commitment Notes.
Analysis · OPTH · Life Sciences
This filing adds the specific terms of the US$100 million equity line of credit first announced on August 14, 2026. The company issued a US$1.5 million convertible note as a commitment fee, with a second US$500,000 note contingent on drawing US$7 million. Draws are priced at a 3% discount to the lower of the purchase-date low or VWAP, with a floor at 85% of the prior close. The notes convert at 95% of the 20-day VWAP with a US$3.00 floor, and a 2.99% ownership blocker limits Seven Knots' stake. The Form F-1 registration is pending SEC effectiveness, so no shares can be sold yet. The discount pricing and convertible notes create potential dilution, but the facility provides flexible access to capital for a company that reported a US$5.7 million net loss in Q3 FY2026.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30% of the 1973 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OPTH was trading at $4.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.1M. The 52-week trading range was $3.12 to $8.84. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.